Diagnosis And Treatment Of ANCA-Associated VasculitisⅡ

The diagnosis of ANCA-associated vasculitis relies on information from clinical evaluation, serologic testing, radiologic findings, and pathologic findings. Approximately 60% of patients with ANCA-associated vasculitis report delays in diagnosis. The median time between the onset of symptoms and final diagnosis was 6 months. The time to diagnosis depends on the organs involved at presentation. For example, patients presenting with painless symptoms of the upper respiratory tract are more likely to pose a diagnostic challenge than patients presenting with rapidly progressive pulmonary-renal syndrome.

Click to Cistanche for kidney disease

This difference is due to the fact that patients with localized disease of the ear, nose, and throat are often ANCA-negative and the imaging findings are less specific. Furthermore, upper respiratory tract biopsies often have a low diagnostic yield, showing nonspecific inflammation rather than granulomatous disease, with only one-third of biopsies showing vasculitis. Table 1 summarizes the diagnostic yield of biopsies from different sites in patients with PR3-ANCA-associated vasculitis and MPO-ANCA-associated vasculitis.

The initial evaluation of patients with suspected ANCA-associated vasculitis requires a systematic approach to determine the extent of organ involvement, of which there are several common organ manifestations that occur with varying frequency.

Due to the variable nature of ANCA-associated vasculitis, almost any organ may be affected, not just those considered classic (eg, kidneys, respiratory system, and skin). Uncommon disease features, such as meningitis and prostatitis, predispose to infection or malignancy, so confirming the diagnosis of ANCA-associated vasculitis often requires collaboration between medicine, surgery, radiology, and pathology.

Increased acute phase reactants, such as C-reactive protein, erythrocyte sedimentation rate, and platelet count, are found in most patients with active disease. However, in the absence of infection, procalcitonin concentrations are usually within the normal range. Patients with active ANCA-associated vasculitis also often present with long-term inflammation, including anemia of chronic disease. The results of additional blood tests and radiology tests are affected by the organs involved.

The predictive value of a positive perinuclear (p-ANCA) or cytoplasmic (c-ANCA) pattern detected in serum immunofluorescence studies was significantly lower than that of a positive MPO-ANCA or PR3-ANCA result detected by enzyme immunoassay. If the only serological evidence of ANCA comes from indirect immunofluorescence analysis without confirmation of PR3-ANCA or MPO-ANCA by immunoassay, the main approach to diagnosing ANCA-associated vasculitis, as opposed to mimics such as lupus, sarcoidosis, or infection The form is unlikely. Furthermore, in primary ANCA-associated vasculitis, there was strong agreement between immunofluorescence and immunoassay results; p-ANCA immunofluorescence corresponded to MPO-ANCA immunofluorescence, and c-ANCA immunofluorescence corresponded to PR3-ANCA Immunofluorescence corresponds. Discordant ANCA test results (eg, c-ANCA immunofluorescence associated with MPO-ANCA positivity) usually indicate drug-induced conditions.

There is substantial overlap between PR3-ANCA and MPO-ANCA disease subgroups. Skin, joints, and peripheral nerves are involved and are largely indistinguishable. However, specific disease features are almost exclusively observed in MPO-ANCA-associated vasculitis or PR3-ANCA-associated vasculitis. For example, usual interstitial pneumonia is a pulmonary finding that is almost always associated with MPO-ANCA-associated vasculitis, and cavitary pulmonary nodules are primarily restricted to patients with PR3-ANCA-associated vasculitis.

There are also subtle differences in renal manifestations between the two subgroups. Although histopathological findings within the kidney do not allow for identification in any given biopsy, patients with glomerulonephritis due to MPO-A-NCA-associated vasculitis have a wider range of clinical presentations than patients with PR3 ANCA-associated vasculitis. wide.

MPO-ANCA-associated vasculitis affects the kidneys and can manifest as a slowly progressive phenotype with widespread sclerosis at diagnosis, but can also present with fulminant features of rapidly progressive glomerulonephritis. Although this rapidly progressive decline in renal function is typical of PR3 ANCA-associated vasculitis, more MPO-ANCA-associated vasculitides reach end-stage renal disease or end-stage renal damage. Active ANCA-associated vasculitis is associated with a hypercoagulable state, and venous thromboembolism is a common finding, especially around the time of diagnosis and initiation of treatment.

How Does Cistanche Treat Kidney Disease?

Cistanche is a traditional Chinese herbal medicine used for centuries to treat various health conditions, including kidney disease. It is derived from the dried stems of Cistanche deserticola, a plant native to the deserts of China and Mongolia. The main active components of cistanche are phenylethanoid glycosides, echinacoside, and acteoside, which have been found to have beneficial effects on kidney health.

Kidney disease, also known as renal disease, refers to a condition in which the kidneys are not functioning properly. This can result in a buildup of waste products and toxins in the body, leading to various symptoms and complications. Cistanche may help treat kidney disease ase through several mechanisms.

Firstly, cistanche has been found to have diuretic properties, meaning it can increase urine production and help eliminate waste products from the body. This can help relieve the burden on the kidneys and prevent the buildup of toxins. By promoting diuresis, cistanche may also help Reduce high blood pressure, a common complication of kidney disease.

Moreover, cistanche has been shown to have antioxidant effects. Oxidative stress, caused by an imbalance between the production of free radicals and the body's antioxidant defenses, plays a key role in the progression of kidney disease. ies help neutralize free radicals and reduce Oxidative stress, thereby protecting the kidneys from damage. The phenylethanoid glycosides found in cistanche have been particularly effective in scavenging free radicals and inhibiting lipid peroxidation.

Additionally, cistanche has been found to have anti-inflammatory effects. Inflammation is another key factor in the development and progression of kidney disease. Cistanche's anti-inflammatory properties help reduce the production of pro-inflammatory cytokines and inhibit the activation of inflammation mandatory pathways, thus alleviating inflammation in the kidneys.

Furthermore, cistanche has been shown to have immunomodulatory effects. In kidney disease, the immune system can be dysregulated, leading to excessive inflammation and tissue damage. Cistanche helps regulate the immune response by modulating the production and activity of immune cells, such as T cells and macrophages. This immune regulation helps reduce inflammation and prevent further damage to the kidneys.

Moreover, cistanche has been found to improve renal function by promoting the regeneration of renal tubes with cells. Renal tubular epithelial cells play a crucial role in the filtration and reabsorption of waste products and electrolytes. In kidney disease, these cells can be damaged, leading to damaged renal function. Cistanche's ability to promote the regeneration of these cells helps restore proper renal function and improve overall kidney health.

In addition to these direct effects on the kidneys, cistanche has been found to have beneficial effects on other organs and systems in the body. This holistic approach to health is particularly important in kidney disease, as the condition often affects multiple organs and systems. che has been shown to have protective effects on the liver, heart, and blood vessels, which are commonly affected by kidney disease. By promoting the health of these organs, cistanche helps improve overall kidney function and prevent further complications.

In conclusion, cistanche is a traditional Chinese herbal medicine used for centuries to treat kidney disease. Its active components have diuretic, antioxidant, anti-inflammatory, immunomodulatory, and regenerative effects, which help improve renal function and protect the kidneys from further damage. , cistanche has beneficial effects on other organs and systems, making it a holistic approach to treating kidney disease.